Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn

In animal studies, deep IgG lowering similar to batoclimab with no or minimal impact on albumin and low-density lipoprotein was observed.  Plan to submit IND and initiate Phase 1 study in... | September 28, 2022

Related Keywords

Chau Cheng ,Pete Salzmann ,Demyelinating Polyneuropathy ,Exchange Commission ,Immunovant Inc ,Nasdaq ,Globenewswire Inc ,Investor Day ,Investor Relations ,Chief Executive Officer ,Myasthenia Gravis ,Thyroid Eye Disease ,Chronic Inflammatory Demyelinating Polyneuropathy ,Grave Disease ,Warm Autoimmune Hemolytic Anemia ,Private Securities Litigation Reform Act ,Annual Report ,Immunovant ,Nc Stock Exchange ,News ,Information ,Press Release ,N ,Animal ,Jeep ,Egg ,Cowering ,Similar ,O ,Batoclimab ,Ith ,Dr ,Albumin ,End ,Lipoprotein ,Gas ,Plan ,Ubmit ,Nitiate ,Hase , ,Tudy Imvt Us45258j1025 ,